Renal Cancer - Results from #220

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. August 6, 2024

Germline Susceptibility to Renal Cell Carcinoma and Implications for Genetic Screening. August 5, 2024

Identification of prognostic RNA editing profiles for clear cell renal carcinoma. August 5, 2024

Myocarditis Following Pembrolizumab Plus Axitinib, and Belzutifan Plus Lenvatinib for Renal Cell Carcinoma: A Case Report. August 2, 2024

Upfront versus deferred cytoreductive nephrectomy following targeted or immunotherapy: a population-based propensity score-matched analysis of perioperative complications. August 2, 2024

Radiodensities of skeletal muscle and visceral adipose tissues are prognostic factors in clear cell renal cell carcinoma. August 1, 2024

Percutaneous ablation versus robotic‑assisted partial nephrectomy for cT1 renal cell carcinoma: an evidence-based analysis of comparative outcomes. August 1, 2024

Feasibility of a Smartphone Application for Education and Symptom Management of Patients With Renal Cell Carcinoma on Combined Tyrosine Kinase and Immune Checkpoint Inhibitors. July 31, 2024

Surgical and Oncological Outcomes of Level III-IV Versus Level I-II Inferior Vena Cava Thrombectomy: A Decennial Experience of a High-Volume European Referral Center. July 31, 2024

Approaches to Treating High Risk and Advanced Renal Cell Carcinoma (RCC): Key Trial Data That Impacts Treatment Decisions in the Clinic. July 30, 2024

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302). July 30, 2024

Evaluating the Urinary Exosome microRNA Profile of von Hippel Lindau Syndrome Patients with Clear Cell Renal Cell Carcinoma. July 30, 2024

Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214. July 30, 2024

Genotype Phenotype Correlation of Renal Tumors in the Cancer Genome Atlas Database. July 29, 2024

Research on molecular characteristics of ADME-related genes in kidney renal clear cell carcinoma. July 29, 2024

Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab. July 26, 2024

Systemic therapies and primary tumour downsizing in renal cell carcinoma: a real-world comparison of anti-angiogenic and immune checkpoint inhibition regimens. July 26, 2024

Surgeon Skill and Perioperative Outcomes in Robot-Assisted Partial Nephrectomy July 25, 2024

Identifying the facilitators and barriers to implementation of renal tumour biopsy in the diagnostic pathway for small renal masses. July 25, 2024

Effective symptom relief through continuous integration of palliative care in advanced renal cell carcinoma patients: comprehensive measurement using the palliative care base assessment. July 25, 2024

Page 12 of 456